Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Maintenance therapy with CC-486 for acute myeloid leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.19
Views: 1251

Prof Andrew Wei - Monash University, Melbourne, Australia

Prof Andrew Wei speaks to ecancer at the 2019 ASH meeting in Orlando about results from the QUAZAR AML-001 trial.

The trial aim was to investigate if maintenance therapy with CC-486 (an oral formulation of azacitidine) could lead to improvements in overall survival of acute myeloid leukaemia (AML) patients in first remission.

Prof Wei reports improvements in overall survival, relapse-free survival and benefits across different prognostic subsets of AML.

This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.

Watch the press conference here.

Read more about the study here.  

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation